The Impact of Myo- inositol supplementation to prevent gestational diabetes in overweight pregnant women

Determine the effect of myo_inositol supplementation to prevent gestational diabetes in overweight pregnant women.

In this study, 114 pregnant women with a gestational age of at least 14 weeks who are referred to the prenatal clinics of Rouhani and Yahya Nejad Hospitals are selected. The participants were divided With a block size of 4, into two groups of A and B (intervention and control) by selecting the number of (0 - 6) are randomly assigned using computer software.

In this study, the participants, if the fasting glucose is less than 92 mg / dl or randomized glucose is less than 200, and other conditions for entry into the study are included. After describing the method of research and side effects of the drug and obtaining written consent, they are included in the study. Triglyceride, cholesterol, LDL, HDL, fasting blood sugar , fasting insulin, insulin sensitivity are checked according to routine laboratory tests and then them randomly divided into two groups. In group A( n = 57 ), people treated with myo-inositol supplementation powder containing 1000 mg of myo-inositol and 200 mcg of folic acid (manufactured by the company Lo.Li Pharma) once a day (one sachet dissolved in a glass of water every night) from the gestational age of (from 14 weeks to 24 weeks) and the group B ( n = 57 ) are received placebo once a day for a total of 10 weeks.

Inclusion criteria: Conscious written consent, pregnant women with singleton pregnancy, age above 18 years old, gestational age 14 weeks, per-pregnancy BMI >= 25 and less than 30 kg /m2, fasting glucose less than 92 mg /dL or Random glucose less than 200 mg /dL, no chronic diseases such as diabetes, high blood pressure and cardiovascular disease, non-smoking and alcohol. Exclusion criteria: The death experience of one of the first-degree relatives during pregnancy, Treatment with corticosteroids during pregnancy.

Intervention group: Myo-inositol supplementation powder the inofulic commercial name containing 2000 mg of myo-inositol and 200 μg of folic acid (manufactured by the company Lo.Li Pharma ) once a day (one sachet dissolved in a glass of water every night) from the gestational age of 14 weeks to 24 weeks in Lo.Li Pharma Manufacturer company) for a total of 10 weeks. Control group: Placebo (folic acid powder 400 mcg + wheat flour total 1 grams) Once a day (one sachet dissolved in a glass of water every night) from the gestational age 14 weeks to 24 weeks for a total of 10 weeks .

primary outcome: Gestational diabetes mellitus (Abnormal oral glucose tolerance test). Secondary outcomes: Neonatal and pregnancy outcomes and side effect of drug

Babol University of Medical Sciences,Governmental

Blocked randomization With a block size of 4, for two groups (A, B). Random numbers (0 - 6) was generated using computer software.

Blind groups include: participant, clinical caregiver, researcher, outcome evaluator, data analyst. Double blind study. Medications and placebo are coded by someone other than the investigator as group (1 and 2) and the investigator do not know which group is related to the drug. The subjects are satisfied and informed that they may be Instead of medication, placebo is given to them. The distribution method With a block size of 4, for two groups (A, B). Random numbers (0 - 6) was generated using computer software.